Award of Shares under Share Incentive Plan

Creo Medical Group PLC

06 July 2026

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Award of Shares under Share Incentive Plan and Director Dealings

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020, which is available to all of the Company's UK based employees, including Directors.

The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 143,541 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.144 per Ordinary Share on 1 July 2026 to meet its obligations under the SIP (the "Partnership Shares").  Under the terms of the SIP, the Company is required to issue or make available to the SIP, to be allocated to participants, two Ordinary Shares in the Company for each Partnership Share purchased (being 287,082 Ordinary Shares, the "Matching Shares").  As at 1 July 2026, Fiduchi held 875,247 unallocated Ordinary Shares within the SIP. 287,082 of these unallocated Ordinary Shares will be utilised to meet the SIP Matching Share obligation and, accordingly, no new Ordinary Shares are required to be issued to satisfy the Company's obligations under the SIP.

Craig Gulliford and Richard Rees, executive directors of the Company (the "Participating Directors"), have acquired Partnership Shares at a price of £0.144 per share at Fiduchi's sole discretion and received Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following the Transaction, the Participating Directors' shareholdings in the Company are as set out in the table below:

Director	Total number of Ordinary Shares purchased or awarded under SIP	Total number of Ordinary Shares held post Transaction
Craig Gulliford, CEO	18,750	2,062,3851
Richard Rees, CFO	18,750	3,417,0792

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.

Notes:

¹ Includes shares held by a PCA of Mr Gulliford.

² Includes shares held by PCAs of Mr Rees.

For further information please contact: 

Creo Medical Group plc		www.creomedical.com
Richard Craven, Company Secretary		Via Walbrook PR
Shore Capital (Nominated Adviser and Corporate Broker) Daniel Bush / Lucy Bowden		[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

1 Details of person discharging managerial responsibilities / person closely associated
a)	Name	Craig Gulliford
2 Reason for the notification
a)	Position / status	CEO
b)	Initial notification / amendment	Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Purchase of Ordinary Shares under Share Incentive Plan at the sole discretion of Fiduchi
c)	Price(s) and volume(s)	Prices Volume(s) £0.144 6,250
d)	Aggregated information Aggregated volume Price	N/A - Single transaction
e)	Date of the transaction	2026-07-01
f)	Place of the transaction	London Stock Exchange

1 Details of person discharging managerial responsibilities / person closely associated
a)	Name	Craig Gulliford
2 Reason for the notification
a)	Position / status	CEO
b)	Initial notification / amendment	Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
c)	Price(s) and volume(s)	Prices Volume(s) £0.001 12,500
d)	Aggregated information Aggregated volume Price	N/A - Single transaction
e)	Date of the transaction	2026-07-01
f)	Place of the transaction	Off-market

1 Details of person discharging managerial responsibilities / person closely associated
a)	Name	Richard Rees
2 Reason for the notification
a)	Position / status	CFO
b)	Initial notification / amendment	Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Purchase of Ordinary Shares under Share Incentive Plan at the sole discretion of Fiduchi
c)	Price(s) and volume(s)	Prices Volume(s) £0.144 6,250
d)	Aggregated information Aggregated volume Price	N/A - Single transaction
e)	Date of the transaction	2026-07-01
f)	Place of the transaction	London Stock Exchange

1 Details of person discharging managerial responsibilities / person closely associated
a)	Name	Richard Rees
2 Reason for the notification
a)	Position / status	CFO
b)	Initial notification / amendment	Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of £0.001 each GB00BZ1BLL44
b)	Nature of the transaction	Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
c)	Price(s) and volume(s)	Prices Volume(s) £0.001 12,500
d)	Aggregated information Aggregated volume Price	N/A - Single transaction
e)	Date of the transaction	2026-07-01
f)	Place of the transaction	Off-market

 

END